Cipla shares in focus as firm gets approval to market Afrezza insulin inhalation powder in India; check details

Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus.

By bringing a game-changing, patient-centered solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease, the Mumbai-based company said in a statement.

Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins, which are given as injections.

The effect of the drug lasts for about 2-3 hours, and it closely resembles the body's response to insulin.

This is the first and only non-injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus, the drug firm said.

"By reducing the need for multiple daily insulin injections, we are offering a convenient solution for people living with diabetes mellitus, particularly those who are uncomfortable with needles, helping them manage their condition more effectively," Cipla MD and Global CEO Umang Vohra said.

Cipla Q2 FY25 Results

Drug major Cipla on Tuesday reported a 17% increase in consolidated net profit to ₹1,303 crore for the second quarter ended September 2024, driven by robust sales across markets.

The company had reported a net profit of ₹1,115 crore in the July-September quarter of the last fiscal year.

Its total income from operations rose to ₹7,051 crore in the second quarter compared to ₹6,490 crore in the year-ago period, Cipla said in a regulatory filing.

"In Q2 FY25, we recorded a revenue growth of 9% over the last year with the highest-ever EBITDA margin of 26.7% driven by mix and other operational efficiencies," Cipla MD and Global CEO Umang Vohra said.